ACE2 and COVID-19: This implies that the bioavailability of ACE2 is proportional to COVID-19 susceptibility, a reason why several studies have advocated against the use of Ang II blockers and other agents that up-regulate ACE2 in the management of cardiovascular disease patients [52].